Filing Details

Accession Number:
0001209191-19-062290
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-31 16:37:32
Reporting Period:
2019-12-27
Accepted Time:
2019-12-31 16:37:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1107421 Ziopharm Oncology Inc ZIOP Pharmaceutical Preparations (2834) 841475642
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1641506 Neil James Laurence Cooper C/O Ziopharm Oncology, Inc.
One First Avenue, Parris Bldg. 34
Boston MA 02129
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-12-27 44,642 $2.24 1,843,967 No 4 M Direct
Common Stock Disposition 2019-12-30 110,694 $4.88 1,733,273 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2019-12-27 44,642 $0.00 44,642 $2.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
487,171 2029-01-06 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.79 to $5.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. 1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.